Skip to main content

About the Lab

 

The vast majority of rare diseases in children are thought to result from underlying variations in the sequence of their DNA. However, distinguishing the specific genetic variants that cause disease and deciphering their functional consequences remains a major challenge. The Younger Lab integrates a series of research programs to accelerate the process of translating the clinical detection of genetic variants into meaningful and actionable biological discoveries.

Leader

 

Dr. Scott Younger is the Director of Disease Gene Engineering within the Genomic Medicine Center at Children's Mercy Kansas City. He has extensive experience working with high-throughput sequencing-based screening technologies and is leading efforts to dissect the molecular mechanisms through which rare genetic variants identified in patients at Children's Mercy lead to disease.

Dr. Younger came to Children's Mercy from the Broad Institute of MIT and Harvard where his group worked on the development of new methodologies to expand the utility of CRISPR-based genetic screens. Prior to working at the Broad Institute, he completed his postdoctoral studies at Harvard University as an American Cancer Society Fellow. He holds a Ph.D. in cell and molecular biology from UT Southwestern Medical Center. He also received an M.S. in biotechnology from the University of Texas at San Antonio and a B.S.I. in bioinformatics from Baylor University.